Mulpleo (Lusutrombopag)

Lusutrombopag, the active ingredient in Mulpleo, is a thrombopoietin receptor agonist presented as a 3 mg tablet for oral use. It treats thrombocytopenia in patients with chronic liver disease undergoing invasive procedures.

GNH USA supplies Mulpleo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lusutrombopag acts on the thrombopoietin receptor pathway to manage low platelet counts.

- Thrombocytopenia in chronic liver disease undergoing invasive procedures: Increases platelet counts to allow safe surgery or diagnostic interventions. - Pre‑operative thrombocytopenia in patients with cirrhosis: Facilitates adequate platelet levels before elective operations. - Platelet deficiency in liver transplant candidates: Supports hemostasis to reduce peri‑operative bleeding risk.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, often transient. - Fatigue: reported during early treatment. - Diarrhoea: usually mild and self‑limiting.

Serious or Rare Side Effects: - Thrombotic events: including portal vein thrombosis. - Hepatic dysfunction: elevated liver enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should assess individual risk factors and monitor relevant parameters. - Bleeding risk assessment: evaluate baseline platelet count and bleeding history. - History of thrombosis: avoid in patients with recent thrombotic episodes. - Liver function monitoring: check hepatic enzymes periodically. - Concurrent anticoagulants: use with caution and adjust dosing as needed. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Lusutrombopag may interact with several drug classes; careful review is recommended.

Major Interactions (Avoid): - Other thrombopoietin receptor agonists: additive effect on platelet production. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase drug exposure and risk of adverse events.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antiplatelet agents (e.g., aspirin, clopidogrel): may alter bleeding risk. - Anticoagulants (e.g., warfarin, DOACs): monitor coagulation parameters. - NSAIDs: increased gastrointestinal bleeding potential.